Loading...
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Schadendorf, D Ascierto, PA Haanen, J Espinosa, E Demidov, L Garbe, C Guida, M Chiarion-Sileni, V Gogas, H
Schadendorf, D
Ascierto, PA
Haanen, J
Espinosa, E
Demidov, L
Garbe, C
Guida, M
Chiarion-Sileni, V
Gogas, H
Citations
Altmetric:
Abstract
Authors
Schadendorf, D
Ascierto, PA
Haanen, J
Espinosa, E
Demidov, L
Garbe, C
Guida, M
Lorigan, Paul C
Chiarion-Sileni, V
Gogas, H
Maio, M
Fierro, MT
Hoeller, C
Terheyden, P
Gutzmer, R
Guren, TK
Bafaloukos, D
Rutkowski, P
Plummer, R
Waterston, A
Kaatz, M
Mandala, M
Marquez-Rodas, I
Munoz-Couselo, E
Dummer, R
Grigoryeva, E
Young, TC
Nathan, P
Ascierto, PA
Haanen, J
Espinosa, E
Demidov, L
Garbe, C
Guida, M
Lorigan, Paul C
Chiarion-Sileni, V
Gogas, H
Maio, M
Fierro, MT
Hoeller, C
Terheyden, P
Gutzmer, R
Guren, TK
Bafaloukos, D
Rutkowski, P
Plummer, R
Waterston, A
Kaatz, M
Mandala, M
Marquez-Rodas, I
Munoz-Couselo, E
Dummer, R
Grigoryeva, E
Young, TC
Nathan, P
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;121:144-53.